Analyst Ratings for bluebird bio (BLUE) [Buys]
BLUE Rating Summary
BLUE Price Target Summary
- Highest: $36.50 (BofA Securities)
- Lowest: $1.00 (Goldman Sachs)
- Average: $8.02
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$8.02 (+694.3%)
* Over Last 12-Mos
Rating Score: 4.2 / 10
Percentile Rank: 42%
Avg. $ Target:
$8.02 (+694.3%)
* Over Last 12-Mos
Rating Score: 4.2 / 10
Percentile Rank: 42%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/19/2023 | BofA Securities » Updated 2/8/2024 |
Jason Gerberry | Upgrade | Buy (Neutral) |
36.50 (30.50) |
3.15 (1.01) |
-67.94% | Details |
| 6/1/2023 | Barclays | Gena Wang | Upgrade | Overweight (Equalweight) |
8.00 (7.00) |
3.31 (1.01) |
-69.49% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
